# US 2026/0076992 A1 · Compositions and methods for treating vaginal atrophy > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2026/0076992 A1 - Document ID: US20260076992A1 - Status: Published application - Kind: A1 - Application number: 19/109,039 - Filed: 2023-09-06 - Published: 2026-03-19 - Earliest claimed: 2022-09-06 - Inventors: Janet Mubo AKANDE; Oreoluwa Olufunmilayo ADEDOYIN - Web page: https://patentgrep.com/patent/US20260076992A1 ## CPC - A61K 31/732: Pectin - A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants} - A61K 9/02: Suppositories; Bougies; Bases therefor; {Ovules}(apparatus for making A61J3/08; devices for introducing into the body A61M31/00) - A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} - A61K 9/08: Solutions {(composition of solutions A61K47/00)} - A61K 31/728: Hyaluronic acid - A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG] - A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers - A61K 47/12: Carboxylic acids; Salts or anhydrides thereof - A61P 15/02: for disorders of the vagina - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Compositions and methods for treating one or more symptoms associated with vaginal atrophy or discomfort are disclosed. The compositions include an effective amount of one or more of the active agents selected from pectin (P), hyaluronic acid (HA), and collagen (Cg), in a pharmaceutically acceptable carrier, for vaginal delivery. The disclosed compositions are useful in treating one or more symptoms associated with vaginal atrophy. Example subjects include postmenopausal women or premenopausal women who experience these symptoms as a result of breastfeeding, intensive vaginal douching, cigarette smoking, autoimmune conditions such as Sjogren's syndrome, pathologic conditions such as diabetes, premature ovarian insufficiency, bilateral oophorectomy, ovarian failure due to radiation or arterial embolization, hypothalamic-pituitary disorders. Additionally, the disclosed compositions are useful in generally alleviating vaginal discomfort such as pH imbalance, vaginal dryness, burning, itching, vaginal discomfort, pain and burning when urinating, dyspareunia (painful sex), and spotting during intercourse. ## Claims ### Claim 1 A composition for treating one or more symptoms associated with vaginal atrophy or discomfort, comprising, an effective amount of an active agent pectin (P) with an optional second active agent selected from the group consisting of hyaluronic acid (HA), collagen (Cg), and a combination of HA and Cg, in a pharmaceutically acceptable carrier, for vaginal delivery, wherein the composition has a pH between 3.5 and 4.5. ### Claim 2 (depends on 1) The composition of claim 1, comprising an effective amount of P only. ### Claim 3 (depends on 1) The composition of claim 1, comprising an effective amount of P in combination with HA. ### Claim 4 (depends on 1) The composition of claim 1, comprising an effective amount of P in combination with Cg. ### Claim 5 (depends on 1) The composition of claim 1, comprising an effective amount of P, HA, and Cg. ### Claim 6 (depends on 1) The composition of claim 1, wherein the pharmaceutically acceptable carrier comprises at least one of glycerin and phenoxyethanol. ### Claim 7 (depends on 1) The composition of claim 1, wherein the pharmaceutically acceptable carrier further comprising lactic acid. ### Claim 8 (depends on 1) The composition of claim 1, further comprising additives. ### Claim 9 (depends on 1) The composition of claim 1, further comprising additives to provide delayed release. ### Claim 10 (depends on 1) The composition of claim 1, having a consistency of a gel. ### Claim 11 (depends on 1) The composition of claim 1, having a consistency of a viscous liquid. ### Claim 12 (depends on 1) The composition of claim 1, comprising by w/w %, 0.1-30% pectin, 0-15% Cg, and 0-10% HA. ### Claim 13 (depends on 1) The composition of claim 1, comprising by w/w %, 0.1-30% glycerin, 0-5% lactic acid, 0-1% phenoxyethanol, and 9-90% water. ### Claim 14 (depends on 1) A formulation comprising the composition of claim 1, formulated into a gel. ### Claim 15 (depends on 1) A formulation comprising the composition of claim 1, formulated into a vaginal suppository. ### Claim 16 (depends on 12) The formulation of claim 12, wherein the formulation is encapsulated in a vaginal applicator. ### Claim 17 (depends on 1) A formulation comprising the composition of claim 1, infused into a sheet of absorbent or porous material to form a tissue, a wipe, a towel, a towelette, or the like. ### Claim 18 (depends on 1) A method of treating one or more symptoms associated with vaginal atrophy or discomfort, comprising administering the composition or formulation of claim 1, to a subject in need thereof. ### Claim 19 (depends on 18) The method of claim 18, wherein the one or more symptoms are selected from the group consisting of pH imbalance, vaginal dryness, burning, itching, vaginal discomfort, pain and burning when urinating, dyspareunia (painful sex), and spotting during intercourse. ### Claim 20 (depends on 18) The method of claim 18, wherein the subject is a postmenopausal women.